<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828932</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-017</org_study_id>
    <nct_id>NCT00828932</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment</brief_title>
  <official_title>An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is&#xD;
      required in patients with mild or moderate hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of lorcaserin</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Lorcaserin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <arm_group_label>Lorcaserin 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged between 18 and 75 years (inclusive)&#xD;
&#xD;
          2. Able to give signed informed consent&#xD;
&#xD;
          3. Hepatic function will fall into one of the following categories:&#xD;
&#xD;
               -  One-third of patients will have normal hepatic function (defined as having all of&#xD;
                  the following parameters within the normal range of the clinical laboratory used&#xD;
                  for this trial: AST, ALT, alkaline phosphatase, total bilirubin)&#xD;
&#xD;
               -  One-third of patients will have mild impairment (Child-Pugh score 5-6)&#xD;
&#xD;
               -  One-third of patients will have moderate impairment (Child-Pugh score 7-9)&#xD;
&#xD;
          4. All subjects will have a BMI of 27-45 kg/m2, inclusive.&#xD;
&#xD;
          5. Eligible male and female patients must agree not to participate in a conception&#xD;
             process&#xD;
&#xD;
          6. Considered to be in stable health in the opinion of the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior participation in any study of lorcaserin.&#xD;
&#xD;
          2. Clinically significant new illness in the 1 month before screening&#xD;
&#xD;
          3. Not suitable to participate in the study in the opinion of the Investigator including&#xD;
             an existing physical or mental condition that prevents compliance with the protocol&#xD;
&#xD;
          4. History of any of the following cardiovascular conditions:&#xD;
&#xD;
               -  Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG),&#xD;
                  CVA, TIA or RIND within 6 months of screening&#xD;
&#xD;
               -  Cardiac arrhythmia requiring initiation of new medical or surgical treatment&#xD;
                  within 6 months of screening (stable medical therapy for &gt; 6 months, pacemakers&#xD;
                  and/or defibrillators implanted &gt; 6 months prior to screening are acceptable)&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
          5. Surgically implanted portacaval shunts are excluded with the following exception:&#xD;
             transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no&#xD;
             less than 3 months prior to dosing&#xD;
&#xD;
          6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell&#xD;
             carcinoma with clean surgical margins)&#xD;
&#xD;
          7. Initiation of a new prescription medication within 1 month prior to screening.&#xD;
&#xD;
          8. Recent history (within 3 months prior to the screening visit) of alcohol or&#xD;
             drug/solvent abuse or a positive screen for drugs of abuse at screening.&#xD;
&#xD;
          9. Use of SSRI's, SNRI's, and other medications must meet the required washout periods.&#xD;
&#xD;
         10. Participated in any clinical study with an investigational drug, biologic, or device&#xD;
             within 1 month prior to dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

